研究者業績
基本情報
研究分野
1論文
52-
Fujita Medical Journal 9(2) 80-83 2023年5月 査読有り責任著者
-
Heart and vessels 36(12) 1856-1860 2021年12月 査読有りThe study aimed to identify factors related to bone mineral density (BMD) among older patients with heart failure (HF). A total of 70 consecutive patients with HF aged 65 years or older who were admitted to an acute hospital due to worsening condition were enrolled before discharge. BMD of the femoral neck was evaluated using the DEXA method. Physical function, as well as echocardiographic and laboratory findings including biomarker of HF severity were collected. Bivariate and multiple regression analyses were employed to determine the association between BMD and the clinical variables. Bivariate analysis determined that age, grip strength, walking speed, serum albumin, and N-terminal pro B-type natriuretic peptide (NT-proBNP) were significantly correlated with BMD (P < 0.01), whereas other clinical parameters were not. The multiple regression analysis identified NT-proBNP as an independent related factor for BMD after adjusting with confounding clinical variables. NT-proBNP was independently related to BMD among older patients with HF. Our results suggest the inclusion of bone fracture prevention strategies in disease management programs, especially for older patients with HF.
-
Journal of Clinical Medicine 10(16) 3564-3564 2021年8月13日 査読有りThe prognostic role of D-dimer in different types of heart failure (HF) is poorly understood. We investigated the prognostic value of D-dimer on admission, both independently and in combination with the Get With The Guidelines—Heart Failure (GWTG-HF) risk score and N-terminal pro-B-type natriuretic peptide (NT-proBNP), in patients with preserved left ventricular ejection fraction (LVEF) and acute decompensated HF (HFpEF) or reduced LVEF (HFrEF). Baseline D-dimer levels were measured on admission in 1670 patients (mean age: 75 years) who were hospitalized for worsening HF. Of those patients, 586 (35%) were categorized as HFpEF (LVEF ≥ 50%) and 1084 as HFrEF (LVEF < 50%). During the 12-month follow-up period after admission, 360 patients died. Elevated levels (at least the highest tertile value) of D-dimer, GWTG-HF risk score, and NT-proBNP were all independently associated with mortality in all HFpEF and HFrEF patients (all p < 0.05). Adding D-dimer to a baseline model with a GWTG-HF risk score and NT-proBNP improved the net reclassification and integrated discrimination improvement for mortality greater than the baseline model alone in all populations (all p < 0.001). The number of elevations in D-dimer, GWTG-HF risk score, and NT-proBNP were independently associated with a higher risk of mortality in all study populations (HFpEF and HFrEF patients; all p < 0.001). The combination of D-dimer, which is independently predictive of mortality, with the GWTG-HF risk score and NT-proBNP could improve early prediction of 12-month mortality in patients with acute decompensated HF, regardless of the HF phenotype.
-
Fujita medical journal 7(1) 18-22 2021年 査読有り責任著者OBJECTIVES: MicroRNAs (miRNA) are functional RNAs that have emerged as pivotal gene expression regulators in cardiac disease. Although several cardiomyocyte miRNAs have been reported to play roles in heart failure progression among patients with idiopathic dilated cardiomyopathy (DCM), the role of circulating miRNAs has not yet been well-examined. METHODS: After total RNA extraction from the peripheral blood samples of three control participants and six patients with DCM, miRNA profiling was performed using miRNA arrays. Based on the results of this initial screening, real-time polymerase chain reaction (RT-PCR) was used to perform a quantitative analysis of blood samples from a larger number of matched patients (DCM, n=20; controls, n=5). Finally, the correlations between specific miRNA expression levels and hemodynamic parameters were analyzed. RESULTS: A primary screening of 2,565 miRNAs resulted in the identification of nine miRNA candidates. Quantitative RT-PCR results revealed significantly increased miR-489 expression levels in the DCM group. Moreover, there was a significant positive correlation between miR-489 expression level and left ventricular ejection fraction. CONCLUSIONS: Our results suggest that circulating miR-489 could be a potential noninvasive diagnostic biomarker for DCM. Additionally, the quantification of circulating miR-489 may have value as a potential prognostic marker for patients with DCM.
-
Fujita medical journal 7(3) 76-82 2021年 査読有り責任著者OBJECTIVES: There are benefits of exercise-based cardiac rehabilitation (CR) in patients with heart failure (HF), but their underlying molecular mechanisms remain elusive. The effect of CR on the expression profile of circulating microRNAs (miRNAs), which are short noncoding RNAs that regulate posttranscriptional expression of target genes, is unknown. If miRNAs respond to changes following CR for HF, then serum profiling of miRNAs may reveal cardioprotective mechanisms of CR. METHODS: This study enrolled three hospitalized patients with progressed systolic HF and three normal volunteer controls. In patients, CR was initiated after improvement of HF, which included 2 weeks of bicycle ergometer and resistance exercises. Genome-wide expression profiling of circulating miRNAs was performed using microarrays for the patients (mean±SD age, 60.0±12.2 years) and controls (58.7±0.58 years). Circulating miRNA expression profiles were compared between patients with HF before and after CR and the controls. RESULTS: Expression levels of two miRNAs were significantly different in patients before CR compared with controls and patients after CR. The expression of hsa-miR-125b-1-3p was significantly downregulated and that of hsa-miR-1290 was significantly upregulated in patients before CR. CONCLUSIONS: When performing CR, expression of certain circulating miRNAs in patients with HF is restored to nonpathological levels. The benefits of CR for HF may result from regulation of miRNAs through multiple effects of gene expression.
MISC
81-
Journal of Cardiology 72 452-457 2018年12月1日
-
臨床病理 = The official journal of Japanese Society of Laboratory Medicine : 日本臨床検査医学会誌 65(10) 1087-1091 2017年10月
-
HEART AND VESSELS 32(5) 609-617 2017年5月
-
HEART AND VESSELS 32(3) 279-286 2017年3月
-
CIRCULATION JOURNAL 81(1) 28-29 2017年1月
-
DRUG AND CHEMICAL TOXICOLOGY 40(1) 110-114 2017年1月
-
Heart and Vessels 31 957-962 2016年6月1日
-
Clinical and experimental nephrology 20(3) 416-24 2016年6月 査読有り
-
Internal Medicine 55(3) 323-323 2016年2月1日
-
Atherosclerosis 243(2) 349-55 2015年12月 査読有り
-
Nagoya J Med Sci. 77(1) 155-166-166 2015年 査読有り
-
Coronary Artery Disease 26 60-65 2015年 査読有り
-
Internal Medicine 54 31-35 2015年1月1日
-
International Heart Journal 56(4) 415-420 2015年1月1日
-
日本医療薬学会年会講演要旨集 24 370-370 2014年8月25日
-
International Journal of Cardiology 167(2) 613-617 2013年7月31日
-
CLINICAL AND EXPERIMENTAL NEPHROLOGY 17(2) 316-316 2013年4月
-
AMERICAN JOURNAL OF CARDIOLOGY 111(5) 712-716 2013年3月 査読有り
-
ATHEROSCLEROSIS 227(1) 130-134 2013年3月 査読有り
-
International Journal of Cardiology 163(2) 214-216 2013年2月20日 査読有り
-
International Journal of Cardiology 162(2) 123-128 2013年1月10日 査読有り
-
JOURNAL OF CARDIOLOGY 61(1-2) 188-188 2013年1月
-
Circulation Journal 77(5) 1229-1234 2013年 査読有り
-
Int J Cardiol 2012年11月15日 査読有り
-
JOURNAL OF CARDIOLOGY 60(3-4) 264-269 2012年9月 査読有り
-
NAGOYA JOURNAL OF MEDICAL SCIENCE 74(3-4) 253-259 2012年8月 査読有り
-
CIRCULATION JOURNAL 76(7) 1609-1615 2012年7月 査読有り
-
NEPHROLOGY DIALYSIS TRANSPLANTATION 27(3) 1059-1063 2012年3月 査読有り
-
CIRCULATION JOURNAL 76(2) 351-355 2012年2月 査読有り
-
INTERNAL MEDICINE 51(9) 1009-1014 2012年 査読有り
書籍等出版物
3講演・口頭発表等
2共同研究・競争的資金等の研究課題
5-
日本学術振興会 科学研究費助成事業 2019年4月 - 2022年3月
-
日本学術振興会 科学研究費助成事業 2016年4月 - 2019年3月
-
日本学術振興会 科学研究費助成事業 2013年4月 - 2016年3月
-
日本学術振興会 科学研究費助成事業 2010年 - 2012年
-
日本学術振興会 科学研究費助成事業 2006年 - 2007年